102 related articles for article (PubMed ID: 2175057)
21. Monitoring of cyclosporine blood levels with polyclonal and monoclonal assays during episodes of renal graft dysfunction.
Martinez L; Foradori A; Vaccarezza A; Martinez P; Rodriguez L
Transplant Proc; 1989 Feb; 21(1 Pt 2):1490-1. PubMed ID: 2652479
[No Abstract] [Full Text] [Related]
22. Evaluation of class II major histocompatibility complex antigen expression for the differential diagnosis of cyclosporine A nephrotoxicity from kidney graft rejection.
Barrett M; Milton AD; Barrett J; Taube D; Bewick M; Parsons VP; Fabre JW
Transplant Proc; 1987 Feb; 19(1 Pt 2):1769-71. PubMed ID: 3152634
[No Abstract] [Full Text] [Related]
23. A comparison of the clinical, histopathologic, cytologic, and biochemical features of renal transplant rejection, cyclosporine A nephrotoxicity, and stable renal function.
Taube D; Neild G; Hobby P; Holt D; Welsh K; Cameron JS
Transplant Proc; 1985 Aug; 17(4 Suppl 1):179-84. PubMed ID: 3895658
[No Abstract] [Full Text] [Related]
24. DDAVP does not induce the release of thrombomodulin from endothelial cells.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Tsubouchi J; Nagai T; Shibata A
Thromb Haemost; 1991 Apr; 65(4):451. PubMed ID: 1647554
[No Abstract] [Full Text] [Related]
25. Calcium channel blockers and early cyclosporine nephrotoxicity after renal transplantation: a prospective randomized study.
Morales JM; Andrés A; Alvarez C; Prieto C; Ortuño B; Ortuño T; Paternina ER; Hernandez Poblete G; Praga M; Ruilope LM
Transplant Proc; 1990 Aug; 22(4):1733-5. PubMed ID: 2389446
[No Abstract] [Full Text] [Related]
26. Cyclosporine-associated renal arteriopathy.
Sommer BG; Henry ML; Ferguson RM
Transplant Proc; 1986 Apr; 18(2 Suppl 1):151-7. PubMed ID: 3515683
[No Abstract] [Full Text] [Related]
27. Dihydroergotoxine (hydergine) to prevent cyclosporine nephrotoxicity in kidney transplant recipients.
Vincent HH; Wenting GJ; Jeekel J; Schalekamp MA; Weimar W
Transplant Proc; 1987 Feb; 19(1 Pt 2):1737-8. PubMed ID: 3274419
[No Abstract] [Full Text] [Related]
28. Clinical correlations of cyclosporine HPLC and FPIA levels in renal transplant recipients.
Sridhar N; Schroeder TJ; Pesce AJ; First MR
Transplant Proc; 1990 Jun; 22(3):1257-9. PubMed ID: 2190387
[No Abstract] [Full Text] [Related]
29. The use of routinely available clinical data in differentiating renal allograft rejection from cyclosporine nephrotoxicity.
Chan GL; Hodge EE; Chang HH
Transplantation; 1989 Dec; 48(6):1075-7. PubMed ID: 2595772
[No Abstract] [Full Text] [Related]
30. Predictive value of von Willebrand factor to ristocetin cofactor ratio and thrombin-antithrombin complex levels for hepatic vessel thrombosis and graft rejection after liver transplantation.
Jennings I; Calne RY; Baglin TP
Transplantation; 1994 Apr; 57(7):1046-51. PubMed ID: 8165701
[TBL] [Abstract][Full Text] [Related]
31. The differentiation of acute renal allograft rejection and cyclosporine nephrotoxicity by simple urine cytology.
Williamson EP; Millar RJ; Criddle RA; Sells RA
Transplant Proc; 1987 Feb; 19(1 Pt 2):1785-6. PubMed ID: 3274423
[No Abstract] [Full Text] [Related]
32. Spleen-liver scintiscan: a new technique for distinguishing allograft rejection from cyclosporine nephrotoxicity.
Galishoff ML; Greenstein SM; Yen CY; Lipkowitz GS; Hanson P; Dunn E; Hong JH; Kaufman H; Solomon NA; Butt KM
Transplant Proc; 1987 Feb; 19(1 Pt 2):1795-800. PubMed ID: 3547885
[No Abstract] [Full Text] [Related]
33. Magnetic resonance imaging of renal transplants: its value in the differentiation of acute rejection and cyclosporin A nephrotoxicity.
te Strake L; Schultze Kool LJ; Paul LC; Tegzess AM; Weening JJ; Hermans J; Doornbos J; Bluemm RG; Bloem JL
Clin Radiol; 1988 May; 39(3):220-8. PubMed ID: 3293883
[TBL] [Abstract][Full Text] [Related]
34. Severe endothelial injury in a renal transplant patient receiving cyclosporine.
Fogo A; Hakim RC; Sugiura M; Inagami T; Kon V
Transplantation; 1990 Jun; 49(6):1190-2. PubMed ID: 2193445
[No Abstract] [Full Text] [Related]
35. Interleukin-2 receptor as an immunodiagnostic tool to differentiate rejection from nephrotoxicity.
Smith AY; Citterio F; Welsh M; Kerman RH; Kahan BD
Transplant Proc; 1989 Feb; 21(1 Pt 2):1462-4. PubMed ID: 2652467
[No Abstract] [Full Text] [Related]
36. Long-term effects of short-term cyclosporine.
Chapman JR; Morris PJ
Transplant Proc; 1986 Apr; 18(2 Suppl 1):186-91. PubMed ID: 3515686
[No Abstract] [Full Text] [Related]
37. [The diagnosis of cyclosporin nephrotoxicity in patients after kidney transplantation].
Rozental' RL; Il'inskiĭ IM; Bitsans IaB; Strokan' VA
Ter Arkh; 1990; 62(6):92-4. PubMed ID: 2218937
[TBL] [Abstract][Full Text] [Related]
38. Differential diagnosis of Cyclosporin A nephrotoxicity versus rejection by fine needle aspiration biopsy.
Häyry P; von Willebrand E; Ahonen J
Proc Eur Dial Transplant Assoc; 1983; 20():356-61. PubMed ID: 6361749
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of cyclosporine therapy in recipients of mismatched living related kidneys.
Flechner SM; Van Buren CT; Kerman RH; Lorber MI; Barker CJ; Golden DL; Kahan BD
Transplant Proc; 1986 Apr; 18(2 Suppl 1):44-51. PubMed ID: 3515693
[No Abstract] [Full Text] [Related]
40. HLA-class II antigen induction does not exclude a diagnosis of cyclosporine nephrotoxicity.
Fuggle SV; McWhinnie DL; Morris PJ
Transplant Proc; 1989 Feb; 21(1 Pt 2):1525-6. PubMed ID: 2652491
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
